The role of cullin3-mediated ubiquitination of the catalytic subunit of PP2A in TRAIL signaling

Cell Cycle

Volumn 13, Issue 23, 2014, Pages 3750-3758

  Xu, Jing ^a   Zhou, Jun Ying ^a   Xu, Zhengfan ^a   Kho, Dhong Hyo ^a   Zhuang, Zhengping ^b   Raz, Avraham ^a   Wu, Gen Sheng ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

Apoptosis resistance; Cullin3; PP2A; TRAIL; Ubiquitination

Indexed keywords

CASPASE 8; CULLIN; CULLIN 3; DEATH DOMAIN RECEPTOR SIGNALING ADAPTOR PROTEIN; DEATH RECEPTOR; PHOSPHOPROTEIN PHOSPHATASE 2A; PROTEASOME; PROTEIN C; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; CUL3 PROTEIN, HUMAN; PHOSPHOPROTEIN PHOSPHATASE 2; TNFSF10 PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; CANCER CELL; CONTROLLED STUDY; ENZYME ACTIVE SITE; ENZYME ACTIVITY; HUMAN; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; UBIQUITINATION; HEK293 CELL LINE; METABOLISM; PHYSIOLOGY; TUMOR CELL LINE;

CATALYTIC DOMAIN; CELL LINE, TUMOR; CULLIN PROTEINS; HEK293 CELLS; HUMANS; PROTEIN PHOSPHATASE 2; SIGNAL TRANSDUCTION; TNF-RELATED APOPTOSIS-INDUCING LIGAND; UBIQUITINATION;

EID: 84920560881     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/15384101.2014.965068     Document Type: Article

References (40)

1. Eichhorn PJ, Creyghton MP, Wilhelmsen K, van Dam H, Bernards R. A RNA interference screen identifies the protein phosphatase 2A subunit PR55gamma as a stress-sensitive inhibitor of c-SRC. PLoS Genet 2007; 3:e218; PMID:18069897; http://dx.doi.org/10.1371/ journal.pgen.0030218
2. Eichhorn PJ, Creyghton MP, Bernards R. Protein phosphatase 2A regulatory subunits and cancer. Biochim Biophys Acta 2009; 1795:1-15; PMID:18588945
3. Janssens V, Goris J. Protein phosphatase 2A: a highly regulated family of serinethreonine phosphatases implicated in cell growth and signalling. Biochem J 2001; 353:417-39; PMID:11171037; http://dx.doi.org/ 10.1042/0264-6021:3530417
4. Shi Y. Serinethreonine phosphatases: mechanism through structure. Cell 2009; 139:468-84; PMID:19879837; http://dx.doi.org/10.1016/j.cell.2009.10.006
5. Di Como CJ, Arndt KT. Nutrients, via the Tor proteins, stimulate the association of Tap42 with type 2A phosphatases. Genes Development 1996; 10:1904-16; PMID:8756348; http://dx.doi.org/10.1101/gad.10.15. 1904
6. Murata K, Wu J, Brautigan DL. B cell receptor-associated protein alpha4 displays rapamycin-sensitive binding directly to the catalytic subunit of protein phosphatase 2A. Proc Natl Acad Sci U S A 1997; 94:10624-9; PMID:9380685; http://dx.doi.org/ 10.1073/pnas.94.20.10624
7. Kong M, Ditsworth D, Lindsten T, Thompson CB. Alpha4 is an essential regulator of PP2A phosphatase activity. Mol Cell 2009; 36:51-60; PMID:19818709; http://dx.doi.org/10.1016/j.molcel.2009.09.025
8. Hershko A, Ciechanover A. The ubiquitin system. Annu Rev Biochem 1998; 67:425-79; PMID:9759494; http://dx.doi.org/10.1146/annurev. biochem.67.1.425
9. Petroski MD, Deshaies RJ. Function and regulation of cullin-RING ubiquitin ligases. Nat Rev Mol Cell Biol 2005; 6:9-20; PMID:15688063; http://dx.doi.org/ 10.1038/nrm1547
10. Geyer R, Wee S, Anderson S, Yates J, Wolf DA. BTBPOZ domain proteins are putative substrate adaptors for cullin 3 ubiquitin ligases. Mol Cell 2003; 12:783-90; PMID:14527422; http://dx.doi.org/ 10.1016/S1097-2765(03)00341-1
11. Bosu DR, Kipreos ET. Cullin-RING ubiquitin ligases: global regulation and activation cycles. Cell Div 2008; 3:7; PMID:18282298; http://dx.doi.org/10.1186/ 1747-1028-3-7
12. Furukawa M, He YJ, Borchers C, Xiong Y. Targeting of protein ubiquitination by BTB-Cullin 3-Roc1 ubiquitin ligases. Nat Cell Biol 2003; 5:1001-7; PMID:14528312; http://dx.doi.org/10.1038/ncb1056
13. Pintard L, Willis JH, Willems A, Johnson JL, Srayko M, Kurz T, Glaser S, Mains PE, Tyers M, Bowerman B, et al. The BTB protein MEL-26 is a substrate-specific adaptor of the CUL-3 ubiquitin-ligase. Nature 2003; 425:311-6; PMID:13679921; http://dx.doi.org/ 10.1038/nature01959
14. Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK, Sutherland GR, Smith TD, Rauch C, Smith CA, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995; 3:673-82; PMID:8777713; http://dx.doi.org/10.1016/1074-7613(95)90057-8
15. Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, Ashkenazi A. Induction of apoptosis by Apo- 2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 1996; 271:12687-90; PMID:8663110; http://dx.doi.org/10.1074/jbc.271. 22.12687
16. Ashkenazi A, Dixit VM. Death receptors: signaling and modulation. Science 1998; 281:1305-8; PMID:9721089; http://dx.doi.org/10.1126/science.281.5381.1305
17. Jin Z, El-Deiry WS. Overview of cell death signaling pathways. Cancer Biol Ther 2005; 4:139-63; PMID:15725726; http://dx.doi.org/10.4161/cbt.4.2. 1508
18. Rowinsky EK. Targeted induction of apoptosis in cancer management: the emerging role of tumor necrosis factor-related apoptosis-inducing ligand receptor activating agents. J Clin Oncol 2005; 23:9394-407; PMID:16361639; http://dx.doi.org/10.1200/JCO. 2005.02.2889
19. Leong S, Cohen RB, Gustafson DL, Langer CJ, Camidge DR, Padavic K, Gore L, Smith M, Chow LQ, von Mehren M, et al. Mapatumumab, an antibody targeting TRAIL-R1, in combination with paclitaxel and carboplatin in patients with advanced solid malignancies: results of a phase I and pharmacokinetic study. J Clin Oncol 2009; 27:4413-21; PMID:19652058; http://dx.doi.org/10.1200/JCO.2008.21.7422
20. Mom CH, Verweij J, Oldenhuis CN, Gietema JA, Fox NL, Miceli R, Eskens FA, Loos WJ, de Vries EG, Sleijfer S, et al. Mapatumumab, a fully human agonistic monoclonal antibody that targets TRAIL-R1, in combination with gemcitabine and cisplatin: a phase I study. Clin Cancer Res 2009; 15:5584-90; PMID:19690193; http://dx.doi.org/10.1158/1078-0432.CCR-09-0996
21. Wu GS. TRAIL as a target in anti-cancer therapy. Cancer Lett 2009; 285:1-5; PMID:19299078; http://dx. doi.org/10.1016/j.canlet.2009.02.029
22. Cheng H, Hong B, Zhou L, Allen JE, Tai G, Humphreys R, Dicker DT, Liu YY, El-Deiry WS. Mitomycin C potentiates TRAIL-induced apoptosis through p53-independent upregulation of death receptors: evidence for the role of c-Jun N-terminal kinase activation. Cell cycle 2012; 11:3312-23; PMID:22895172; http://dx.doi.org/10.4161/cc.21670
23. Saturno G, Valenti M, De Haven Brandon A, Thomas GV, Eccles S, Clarke PA,Workman P. Combining trail with PI3 kinase or HSP90 inhibitors enhances apoptosis in colorectal cancer cells via suppression of survival signaling. Oncotarget 2013; 4:1185-98; PMID:23852390
24. Jin Z, Li Y, Pitti R, Lawrence D, Pham VC, Lill JR, Ashkenazi A. Cullin3-based polyubiquitination and p62-dependent aggregation of caspase-8 mediate extrinsic apoptosis signaling. Cell 2009; 137:721-35; PMID:19427028; http://dx.doi.org/10.1016/j.cell. 2009.03.015
25. Xu J, Zhou JY, Wei WZ, Wu GS. Activation of the Akt survival pathway contributes to TRAIL resistance in cancer cells. PloS One 2010; 5:e10226; PMID:20419107; http://dx.doi.org/10.1371/journal. pone.0010226
26. Xu J, Xu Z, Zhou JY, Zhuang Z, Wang E, Boerner J, Wu GS. Regulation of the Src-PP2A interaction in tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)-induced apoptosis. J Biol Chem 2013; 288:33263-71; PMID:24100030; http://dx.doi. org/10.1074/jbc.M113.508093
27. Rahman M, Davis SR, Pumphrey JG, Bao J, Nau MM, Meltzer PS, Lipkowitz S. TRAIL induces apoptosis in triple-negative breast cancer cells with a mesenchymal phenotype. Breast Cancer Res Treat 2009; 113:217-30; PMID:18266105; http://dx.doi.org/10.1007/s10549- 008-9924-5
28. Favre B, Turowski P, Hemmings BA. Differential inhibition and posttranslational modification of protein phosphatase 1 and 2A in MCF7 cells treated with caly-culin- A, okadaic acid, and tautomycin. J Biol Chem 1997; 272:13856-63; PMID:9153244; http://dx.doi. org/10.1074/jbc.272.21.13856
29. Keane MM, Ettenberg SA, Nau MM, Russell EK, Lipkowitz S. Chemotherapy augments TRAIL-induced apoptosis in breast cell lines. Cancer research 1999; 59:734-41; PMID:9973225
30. Luo J, Shen G, Yan J, He C, Zhang H. AtCHIP functions as an E3 ubiquitin ligase of protein phosphatase 2A subunits and alters plant response to abscisic acid treatment. Plant J 2006; 46:649-57; PMID:16640601; http://dx.doi.org/10.1111/j.1365-313X.2006.02730.x
31. Trockenbacher A, Suckow V, Foerster J, Winter J, Krauss S, Ropers HH, Schneider R, Schweiger S. MID1, mutated in Opitz syndrome, encodes an ubiquitin ligase that targets phosphatase 2A for degradation. Nate Genet 2001; 29:287-94; PMID:11685209; http://dx.doi.org/10.1038/ng762
32. Singer JD, Gurian-West M, Clurman B, Roberts JM. Cullin-3 targets cyclin E for ubiquitination and controls S phase in mammalian cells. Genes Dev 1999; 13:2375-87; PMID:10500095; http://dx.doi.org/ 10.1101/gad.13.18.2375
33. Xu L, Wei Y, Reboul J, Vaglio P, Shin TH, Vidal M, Elledge SJ, Harper JW. BTB proteins are substrate-specific adaptors in an SCF-like modular ubiquitin ligase containing CUL-3. Nature 2003; 425:316-21; PMID:13679922; http://dx.doi.org/10.1038/nature 01985
34. Petroski MD, Deshaies RJ. Mechanism of lysine 48- linked ubiquitin-chain synthesis by the cullin-RING ubiquitin-ligase complex SCF-Cdc34. Cell 2005; 123:1107-20; PMID:16360039; http://dx.doi.org/ 10.1016/j.cell.2005.09.033
35. Nakayama KI, Nakayama K. Ubiquitin ligases: cellcycle control and cancer. Nature reviews Cancer 2006; 6:369-81; PMID:16633365; http://dx.doi.org/ 10.1038/nrc1881
36. Sun L, Chen ZJ. The novel functions of ubiquitination in signaling. Curr Opin Cell Biol 2004; 16:119-26; PMID:15196553; http://dx.doi.org/10.1016/j.ceb. 2004.02.005
37. Harmala-Brasken AS, Mikhailov A, Soderstrom TS, Meinander A, Holmstrom TH, Damuni Z, Eriksson JE. Type-2A protein phosphatase activity is required to maintain death receptor responsiveness. Oncogene 2003; 22:7677-86; PMID:14576831; http://dx.doi. org/10.1038/sj.onc.1207077
38. Barisic S, Strozyk E, Peters N, Walczak H, Kulms D. Identification of PP2A as a crucial regulator of the NFkappaB feedback loop: its inhibition by UVB turns NF-kappaB into a pro-apoptotic factor. Cell Death Diff 2008; 15:1681-90; PMID:18583989; http://dx. doi.org/10.1038/cdd.2008.98
39. Wang J, Zhou JY, Zhang L, Wu GS. Involvement of MKP-1 and Bcl-2 in acquired cisplatin resistance in ovarian cancer cells. Cell Cycle 2009; 8:3191-8; PMID:19755862; http://dx.doi.org/10.4161/cc.8.19. 9751
40. Lu J, Kovach JS, Johnson F, Chiang J, Hodes R, Lonser R, Zhuang Z. Inhibition of serinethreonine phosphatase PP2A enhances cancer chemotherapy by blocking DNA damage induced defense mechanisms. Proc Natl Acad Sci U S A 2009; 106:11697-702; PMID:19564615; http://dx.doi. org/10.1073/pnas.0905930106